drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00277 | DB08931 | 1,031 | 947 | [
"DDInter1791",
"DDInter1600"
] | Theophylline | Riociguat | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Major | 2 | [
[
[
1031,
25,
947
]
],
[
[
1031,
24,
379
],
[
379,
24,
947
]
],
[
[
1031,
23,
1215
],
[
1215,
24,
947
]
],
[
[
1031,
24,
98
],
[
98,
... | [
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Riociguat"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabepr... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Theophylline may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and L... |
DB08890 | DB11110 | 16 | 603 | [
"DDInter1069",
"DDInter1115"
] | Linaclotide | Magnesium citrate | Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin deri... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Minor | 0 | [
[
[
16,
23,
603
]
],
[
[
16,
62,
355
],
[
355,
24,
603
]
],
[
[
16,
62,
355
],
[
355,
24,
57
],
[
57,
24,
603
]
],
[
[
16,
1,
... | [
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactulose"
],
... | Linaclotide may cause a minor interaction that can limit clinical effects when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Lactulose and Lact... |
DB00065 | DB05679 | 581 | 1,683 | [
"DDInter923",
"DDInter1907"
] | Infliximab | Ustekinumab | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Major | 2 | [
[
[
581,
25,
1683
]
],
[
[
581,
23,
1461
],
[
1461,
23,
1683
]
],
[
[
581,
23,
1193
],
[
1193,
62,
1683
]
],
[
[
581,
25,
1042
],
[
1042,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluc... |
DB00035 | DB00502 | 1,314 | 1,300 | [
"DDInter507",
"DDInter853"
] | Desmopressin | Haloperidol | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Moderate | 1 | [
[
[
1314,
24,
1300
]
],
[
[
1314,
24,
543
],
[
543,
63,
1300
]
],
[
[
1314,
21,
28929
],
[
28929,
60,
1300
]
],
[
[
1314,
25,
870
],
[
870... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol
Desmopressin (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused ... |
DB00472 | DB06822 | 758 | 802 | [
"DDInter758",
"DDInter1812"
] | Fluoxetine | Tinzaparin | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Moderate | 1 | [
[
[
758,
24,
802
]
],
[
[
758,
25,
222
],
[
222,
24,
802
]
],
[
[
758,
1,
109
],
[
109,
24,
802
]
],
[
[
758,
24,
1151
],
[
1151,
24... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Fluoxetine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Fluoxetine (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate d... |
DB09068 | DB11979 | 1,427 | 1,320 | [
"DDInter1948",
"DDInter625"
] | Vortioxetine | Elagolix | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1427,
24,
1320
]
],
[
[
1427,
63,
129
],
[
129,
24,
1320
]
],
[
[
1427,
24,
913
],
[
913,
24,
1320
]
],
[
[
1427,
64,
39
],
[
39,
... | [
[
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and... |
DB00669 | DB01105 | 399 | 222 | [
"DDInter1730",
"DDInter1665"
] | Sumatriptan | Sibutramine | Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines. Sumatriptan was granted FDA approval on 28 December 1992. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Major | 2 | [
[
[
399,
25,
222
]
],
[
[
399,
18,
4930
],
[
4930,
57,
222
]
],
[
[
399,
21,
29356
],
[
29356,
60,
222
]
],
[
[
399,
63,
475
],
[
475,
... | [
[
[
"Sumatriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Sumatriptan",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Sumatriptan (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Sibutramine (Compound)
Sumatriptan (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Sibutramine (Compound)
Sumatriptan may cause a moderate interaction that could exacerbate d... |
DB06800 | DB11691 | 1,159 | 1,499 | [
"DDInter1188",
"DDInter1258"
] | Methylnaltrexone | Naldemedine | Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008. | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
1159,
24,
1499
]
],
[
[
1159,
24,
938
],
[
938,
24,
1499
]
],
[
[
1159,
24,
785
],
[
785,
63,
1499
]
],
[
[
1159,
74,
267
],
[
267,
... | [
[
[
"Methylnaltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Methylnaltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
... | Methylnaltrexone may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Methylnaltrexone may cause a moderate interaction that could exacerbate diseases when taken with Capmatin... |
DB00782 | DB01176 | 1,123 | 537 | [
"DDInter1535",
"DDInter453"
] | Propantheline | Cyclizine | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
1123,
24,
537
]
],
[
[
1123,
24,
1511
],
[
1511,
63,
537
]
],
[
[
1123,
24,
104
],
[
104,
1,
537
]
],
[
[
1123,
63,
13
],
[
13,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine a... |
DB09082 | DB11718 | 659 | 927 | [
"DDInter1934",
"DDInter640"
] | Vilanterol | Encorafenib | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
659,
24,
927
]
],
[
[
659,
63,
216
],
[
216,
24,
927
]
],
[
[
659,
24,
1399
],
[
1399,
63,
927
]
],
[
[
659,
24,
938
],
[
938,
2... | [
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
],
... | Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Lithium carb... |
DB08930 | DB09322 | 1,459 | 1,114 | [
"DDInter582",
"DDInter1966"
] | Dolutegravir | Zinc sulfate | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Major | 2 | [
[
[
1459,
25,
1114
]
],
[
[
1459,
62,
1220
],
[
1220,
23,
1114
]
],
[
[
1459,
64,
1596
],
[
1596,
23,
1114
]
],
[
[
1459,
25,
428
],
[
428... | [
[
[
"Dolutegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Dolutegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dex... | Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Dolutegravir may lead to a major life threatening interaction when taken with Iron and Iron may cause a mi... |
DB00072 | DB11601 | 550 | 1,270 | [
"DDInter1846",
"DDInter1889"
] | Trastuzumab | Tuberculin purified protein derivative | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
550,
24,
1270
]
],
[
[
550,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
550,
25,
1064
],
[
1064,
24,
1270
]
],
[
[
550,
25,
1259
],
[
1259,
... | [
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Trastuzumab may lead to a major life threatening interaction when taken with Clad... |
DB00679 | DB01181 | 684 | 1,532 | [
"DDInter1796",
"DDInter906"
] | Thioridazine | Ifosfamide | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
684,
24,
1532
]
],
[
[
684,
6,
3486
],
[
3486,
45,
1532
]
],
[
[
684,
18,
2976
],
[
2976,
57,
1532
]
],
[
[
684,
21,
29209
],
[
29209,... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Thioridazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compoun... | Thioridazine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ifosfamide (Compound)
Thioridazine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Ifosfamide (Compound)
Thioridazine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (Compound... |
DB09498 | DB13915 | 810 | 689 | [
"DDInter1715",
"DDInter146"
] | Strontium chloride Sr-89 | Axicabtagene ciloleucel | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express ant... | Moderate | 1 | [
[
[
810,
24,
689
]
],
[
[
810,
63,
599
],
[
599,
24,
689
]
],
[
[
810,
24,
738
],
[
738,
24,
689
]
],
[
[
810,
63,
976
],
[
976,
25,... | [
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with... | Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate dis... |
DB00694 | DB12010 | 51 | 214 | [
"DDInter485",
"DDInter785"
] | Daunorubicin | Fostamatinib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
51,
24,
214
]
],
[
[
51,
25,
976
],
[
976,
24,
214
]
],
[
[
51,
74,
322
],
[
322,
24,
214
]
],
[
[
51,
24,
1005
],
[
1005,
24,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tof... | Daunorubicin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Daunorubicin (Compound) resembles Epirubicin (Compound) and Daunorubicin may cause a moderate interaction that could exac... |
DB00030 | DB00191 | 1,685 | 73 | [
"DDInter934",
"DDInter1447"
] | Insulin human | Phentermine | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Moderate | 1 | [
[
[
1685,
24,
73
]
],
[
[
1685,
24,
1445
],
[
1445,
63,
73
]
],
[
[
1685,
24,
551
],
[
551,
64,
73
]
],
[
[
1685,
24,
529
],
[
529,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Phen... |
DB01208 | DB11978 | 945 | 124 | [
"DDInter1705",
"DDInter822"
] | Sparfloxacin | Glasdegib | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Major | 2 | [
[
[
945,
25,
124
]
],
[
[
945,
62,
112
],
[
112,
23,
124
]
],
[
[
945,
64,
79
],
[
79,
24,
124
]
],
[
[
945,
40,
739
],
[
739,
24,
... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Sparfloxacin may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cau... |
DB00529 | DB00635 | 789 | 1,573 | [
"DDInter779",
"DDInter1515"
] | Foscarnet | Prednisone | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
789,
24,
1573
]
],
[
[
789,
24,
175
],
[
175,
40,
1573
]
],
[
[
789,
63,
251
],
[
251,
1,
1573
]
],
[
[
789,
24,
167
],
[
167,
1... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (... |
DB00031 | DB00176 | 20 | 529 | [
"DDInter1764",
"DDInter770"
] | Tenecteplase | Fluvoxamine | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Moderate | 1 | [
[
[
20,
24,
529
]
],
[
[
20,
24,
1274
],
[
1274,
63,
529
]
],
[
[
20,
25,
1172
],
[
1172,
24,
529
]
],
[
[
20,
25,
1421
],
[
1421,
6... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Tenecteplase may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ib... |
DB00163 | DB11569 | 1,461 | 1,093 | [
"DDInter1943",
"DDInter1003"
] | Vitamin E | Ixekizumab | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Minor | 0 | [
[
[
1461,
23,
1093
]
],
[
[
1461,
62,
66
],
[
66,
24,
1093
]
],
[
[
1461,
24,
134
],
[
134,
24,
1093
]
],
[
[
1461,
23,
1683
],
[
1683,
... | [
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Efalizumab"
],
[
"E... | Vitamin E may cause a minor interaction that can limit clinical effects when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbi... |
DB00065 | DB01206 | 581 | 37 | [
"DDInter923",
"DDInter1086"
] | Infliximab | Lomustine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | An alkylating agent of value against both hematologic malignancies and solid tumors. | Major | 2 | [
[
[
581,
25,
37
]
],
[
[
581,
24,
697
],
[
697,
23,
37
]
],
[
[
581,
25,
147
],
[
147,
23,
37
]
],
[
[
581,
25,
141
],
[
141,
24,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobar... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Lomustine
Infliximab may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may c... |
DB00477 | DB06655 | 216 | 5 | [
"DDInter363",
"DDInter1077"
] | Chlorpromazine | Liraglutide | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
216,
24,
5
]
],
[
[
216,
24,
870
],
[
870,
24,
5
]
],
[
[
216,
63,
245
],
[
245,
24,
5
]
],
[
[
216,
40,
1630
],
[
1630,
24,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Gl... |
DB00169 | DB00951 | 386 | 1,072 | [
"DDInter367",
"DDInter986"
] | Cholecalciferol | Isoniazid | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Moderate | 1 | [
[
[
386,
24,
1072
]
],
[
[
386,
6,
8374
],
[
8374,
45,
1072
]
],
[
[
386,
75,
1331
],
[
1331,
24,
1072
]
],
[
[
386,
25,
1098
],
[
1098,
... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Cholecalciferol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Co... | Cholecalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isoniazid (Compound)
Cholecalciferol (Compound) resembles Ergocalciferol (Compound) and Cholecalciferol may lead to a major life threatening interaction when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that co... |
DB12500 | DB12887 | 283 | 1,598 | [
"DDInter714",
"DDInter1750"
] | Fedratinib | Tazemetostat | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Major | 2 | [
[
[
283,
25,
1598
]
],
[
[
283,
63,
168
],
[
168,
23,
1598
]
],
[
[
283,
64,
594
],
[
594,
24,
1598
]
],
[
[
283,
63,
985
],
[
985,
... | [
[
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezom... | Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Fedratinib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a ... |
DB00470 | DB12267 | 530 | 1,476 | [
"DDInter601",
"DDInter233"
] | Dronabinol | Brigatinib | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
530,
24,
1476
]
],
[
[
530,
24,
629
],
[
629,
24,
1476
]
],
[
[
530,
63,
854
],
[
854,
24,
1476
]
],
[
[
530,
24,
180
],
[
180,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Nimodipine and Nimodipi... |
DB00283 | DB13913 | 701 | 1,536 | [
"DDInter395",
"DDInter175"
] | Clemastine | Belladonna | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family _Solanaceae_. Its roots, leaves and fruits contain , , and mostly, . These alkaloids are naturally-occurring muscarinic antagonists. is a non-selective muscarinic antagonist that is mainly used as ... | Moderate | 1 | [
[
[
701,
24,
1536
]
],
[
[
701,
24,
849
],
[
849,
24,
1536
]
],
[
[
701,
63,
352
],
[
352,
24,
1536
]
],
[
[
701,
35,
1511
],
[
1511,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium... |
DB00774 | DB01088 | 1,577 | 714 | [
"DDInter889",
"DDInter908"
] | Hydroflumethiazide | Iloprost | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1577,
24,
714
]
],
[
[
1577,
63,
1648
],
[
1648,
24,
714
]
],
[
[
1577,
24,
1450
],
[
1450,
63,
714
]
],
[
[
1577,
1,
323
],
[
323,
... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
... | Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Empag... |
DB00951 | DB06203 | 1,072 | 1,002 | [
"DDInter986",
"DDInter51"
] | Isoniazid | Alogliptin | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
1072,
24,
1002
]
],
[
[
1072,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1072,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
1072,
21,
29013
],
[
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
... | Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Isoniazid (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Isoniazid (Compound) causes Diabetes mellitus (Side Effect) and Di... |
DB01165 | DB01278 | 1,539 | 1,021 | [
"DDInter1325",
"DDInter1506"
] | Ofloxacin | Pramlintide | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1539,
24,
1021
]
],
[
[
1539,
64,
891
],
[
891,
24,
1021
]
],
[
[
1539,
25,
1019
],
[
1019,
63,
1021
]
],
[
[
1539,
63,
485
],
[
485,
... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisolone"
],
[
"Prednisol... | Ofloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Ofloxacin may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate... |
DB00242 | DB09123 | 1,064 | 1,525 | [
"DDInter392",
"DDInter546"
] | Cladribine | Dienogest | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in... | Moderate | 1 | [
[
[
1064,
24,
1525
]
],
[
[
1064,
25,
980
],
[
980,
24,
1525
]
],
[
[
1064,
25,
1303
],
[
1303,
63,
1525
]
],
[
[
1064,
24,
1501
],
[
1501... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dienogest"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizuma... | Cladribine may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Dienogest
Cladribine may lead to a major life threatening interaction when taken with Guselkumab and Guselkumab may cause a moderate int... |
DB00013 | DB08816 | 1,255 | 578 | [
"DDInter1905",
"DDInter1802"
] | Urokinase | Ticagrelor | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1255,
24,
578
]
],
[
[
1255,
23,
297
],
[
297,
62,
578
]
],
[
[
1255,
24,
191
],
[
191,
23,
578
]
],
[
[
1255,
64,
1578
],
[
1578,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clov... | Urokinase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Aminocaproic acid and Aminocaproic ac... |
DB00295 | DB04843 | 475 | 1,511 | [
"DDInter1244",
"DDInter1149"
] | Morphine | Mepenzolate | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
475,
24,
1511
]
],
[
[
475,
25,
675
],
[
675,
24,
1511
]
],
[
[
475,
24,
537
],
[
537,
24,
1511
]
],
[
[
475,
63,
352
],
[
352,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextr... | Morphine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine... |
DB01097 | DB12332 | 1,377 | 1,619 | [
"DDInter1033",
"DDInter1626"
] | Leflunomide | Rucaparib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
1377,
25,
1619
]
],
[
[
1377,
63,
112
],
[
112,
23,
1619
]
],
[
[
1377,
25,
259
],
[
259,
24,
1619
]
],
[
[
1377,
24,
151
],
[
151,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metron... | Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Leflunomide may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may c... |
DB00290 | DB08870 | 329 | 850 | [
"DDInter219",
"DDInter228"
] | Bleomycin | Brentuximab vedotin | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Major | 2 | [
[
[
329,
25,
850
]
],
[
[
329,
24,
496
],
[
496,
63,
850
]
],
[
[
329,
24,
611
],
[
611,
24,
850
]
],
[
[
329,
63,
1184
],
[
1184,
2... | [
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
... | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01041 | DB06691 | 770 | 849 | [
"DDInter1789",
"DDInter1155"
] | Thalidomide | Mepyramine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
770,
24,
849
]
],
[
[
770,
63,
1594
],
[
1594,
24,
849
]
],
[
[
770,
24,
272
],
[
272,
24,
849
]
],
[
[
770,
64,
1648
],
[
1648,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine an... |
DB01075 | DB01224 | 1,376 | 623 | [
"DDInter569",
"DDInter1553"
] | Diphenhydramine | Quetiapine | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
1376,
24,
623
]
],
[
[
1376,
63,
827
],
[
827,
1,
623
]
],
[
[
1376,
24,
851
],
[
851,
1,
623
]
],
[
[
1376,
6,
4304
],
[
4304,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Quetiapine (Co... |
DB00468 | DB11652 | 1,424 | 1,155 | [
"DDInter1557",
"DDInter1891"
] | Quinine | Tucatinib | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
1424,
24,
1155
]
],
[
[
1424,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
1424,
24,
659
],
[
659,
24,
1155
]
],
[
[
1424,
25,
609
],
[
609,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Be... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may ... |
DB00701 | DB05773 | 1,091 | 1,047 | [
"DDInter90",
"DDInter1848"
] | Amprenavir | Trastuzumab emtansine | Amprenavir is a protease inhibitor used to treat HIV infection. | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
1091,
24,
1047
]
],
[
[
1091,
24,
310
],
[
310,
63,
1047
]
],
[
[
1091,
25,
458
],
[
458,
24,
1047
]
],
[
[
1091,
64,
467
],
[
467,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Amprenavir may lead to a major life threatening interaction when taken with Tinidazole and Tinidazo... |
DB00581 | DB01165 | 355 | 1,539 | [
"DDInter1018",
"DDInter1325"
] | Lactulose | Ofloxacin | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
355,
24,
1539
]
],
[
[
355,
63,
1176
],
[
1176,
1,
1539
]
],
[
[
355,
24,
945
],
[
945,
40,
1539
]
],
[
[
355,
24,
739
],
[
739,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxacin"
],
[
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compou... |
DB00983 | DB11853 | 480 | 230 | [
"DDInter776",
"DDInter1577"
] | Formoterol | Relugolix | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
480,
24,
230
]
],
[
[
480,
24,
129
],
[
129,
23,
230
]
],
[
[
480,
24,
1213
],
[
1213,
24,
230
]
],
[
[
480,
63,
79
],
[
79,
24,... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasati... |
DB00031 | DB00686 | 20 | 383 | [
"DDInter1764",
"DDInter1424"
] | Tenecteplase | Pentosan polysulfate | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Moderate | 1 | [
[
[
20,
24,
383
]
],
[
[
20,
24,
714
],
[
714,
63,
383
]
],
[
[
20,
25,
405
],
[
405,
63,
383
]
],
[
[
20,
24,
1061
],
[
1061,
24,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate
Tenecteplase may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabru... |
DB00076 | DB06288 | 1,352 | 607 | [
"DDInter555",
"DDInter77"
] | Digoxin Immune Fab (Ovine) | Amisulpride | Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin. | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Moderate | 1 | [
[
[
1352,
24,
607
]
],
[
[
1352,
25,
57
],
[
57,
25,
607
]
],
[
[
1352,
24,
216
],
[
216,
6,
5289
],
[
5289,
45,
607
]
],
[
[
1352,
... | [
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic t... | Digoxin Immune Fab (Ovine) may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Amisulpride
Digoxin Immune Fab (Ovine) may cause a moderate interaction that could exacerbate diseases when taken with Chlorp... |
DB00476 | DB00501 | 109 | 752 | [
"DDInter608",
"DDInter380"
] | Duloxetine | Cimetidine | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Moderate | 1 | [
[
[
109,
24,
752
]
],
[
[
109,
6,
7950
],
[
7950,
45,
752
]
],
[
[
109,
18,
3682
],
[
3682,
57,
752
]
],
[
[
109,
21,
29134
],
[
29134,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",... | Duloxetine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Cimetidine (Compound)
Duloxetine (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) is downregulated by Cimetidine (Compound)
Duloxetine (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound)
Du... |
DB00934 | DB01268 | 413 | 1,151 | [
"DDInter1124",
"DDInter1731"
] | Maprotiline | Sunitinib | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
413,
24,
1151
]
],
[
[
413,
24,
1311
],
[
1311,
1,
1151
]
],
[
[
413,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
413,
7,
9650
],
[
9650,
... | [
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
... | Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Maprotiline (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Maprotiline (Compound) upregulates HMGCS1 (Gene) and HMGCS1 ... |
DB08865 | DB09061 | 1,593 | 1,627 | [
"DDInter448",
"DDInter284"
] | Crizotinib | Cannabidiol | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Minor | 0 | [
[
[
1593,
23,
1627
]
],
[
[
1593,
63,
723
],
[
723,
23,
1627
]
],
[
[
1593,
25,
760
],
[
760,
62,
1627
]
],
[
[
1593,
64,
609
],
[
609,
... | [
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Crizotinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a... |
DB00381 | DB09280 | 376 | 1,604 | [
"DDInter79",
"DDInter1101"
] | Amlodipine | Lumacaftor | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
376,
25,
1604
]
],
[
[
376,
63,
1061
],
[
1061,
24,
1604
]
],
[
[
376,
24,
593
],
[
593,
24,
1604
]
],
[
[
376,
24,
629
],
[
629,
... | [
[
[
"Amlodipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprost... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bup... |
DB00035 | DB00945 | 1,314 | 1,479 | [
"DDInter507",
"DDInter20"
] | Desmopressin | Acetylsalicylic acid | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Minor | 0 | [
[
[
1314,
23,
1479
]
],
[
[
1314,
24,
1338
],
[
1338,
24,
1479
]
],
[
[
1314,
6,
10522
],
[
10522,
45,
1479
]
],
[
[
1314,
21,
28751
],
[
... | [
[
[
"Desmopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic ac... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Desmopressin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Acetylsalicyli... |
DB00700 | DB01285 | 312 | 708 | [
"DDInter656",
"DDInter445"
] | Eplerenone | Corticotropin | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
312,
24,
708
]
],
[
[
312,
40,
443
],
[
443,
24,
708
]
],
[
[
312,
24,
1450
],
[
1450,
63,
708
]
],
[
[
312,
1,
1561
],
[
1561,
... | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Eplerenone",
"{u} (Compound) resembles {v} (Compound)",
"Spironolactone"
],
[
"Spironolactone",
"{u} may caus... | Eplerenone (Compound) resembles Spironolactone (Compound) and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate inter... |
DB00912 | DB11936 | 473 | 1,030 | [
"DDInter1581",
"DDInter176"
] | Repaglinide | Bempedoic acid | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with el... | Moderate | 1 | [
[
[
473,
24,
1030
]
],
[
[
473,
24,
1450
],
[
1450,
24,
1030
]
],
[
[
473,
63,
891
],
[
891,
25,
1030
]
],
[
[
473,
24,
1486
],
[
1486,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Prednisol... |
DB08907 | DB12015 | 1,344 | 1,033 | [
"DDInter280",
"DDInter53"
] | Canagliflozin | Alpelisib | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1344,
24,
1033
]
],
[
[
1344,
63,
1254
],
[
1254,
24,
1033
]
],
[
[
1344,
24,
861
],
[
861,
63,
1033
]
],
[
[
1344,
24,
1296
],
[
1296... | [
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
... | Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Ri... |
DB06605 | DB08865 | 1,409 | 1,593 | [
"DDInter108",
"DDInter448"
] | Apixaban | Crizotinib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
1409,
24,
1593
]
],
[
[
1409,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1409,
21,
28792
],
[
28792,
60,
1593
]
],
[
[
1409,
62,
307
],
[
30... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Apixaban",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Apixaban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Apixaban (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Crizotinib (Compound)
Apixaban may cause a minor interaction that can limit clinical effects when taken ... |
DB00420 | DB01087 | 508 | 1,520 | [
"DDInter1532",
"DDInter1520"
] | Promazine | Primaquine | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
508,
24,
1520
]
],
[
[
508,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
508,
6,
7950
],
[
7950,
45,
1520
]
],
[
[
508,
23,
112
],
[
112,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydr... | Promazine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Promazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Primaquine (Compound)
Promazine may cause a minor intera... |
DB00008 | DB01229 | 491 | 973 | [
"DDInter1407",
"DDInter1378"
] | Peginterferon alfa-2a | Paclitaxel (protein-bound) | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
491,
24,
973
]
],
[
[
491,
24,
310
],
[
310,
63,
973
]
],
[
[
491,
24,
134
],
[
134,
24,
973
]
],
[
[
491,
25,
990
],
[
990,
63,... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabaz... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00261 | DB01136 | 702 | 772 | [
"DDInter93",
"DDInter305"
] | Anagrelide | Carvedilol | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
702,
24,
772
]
],
[
[
702,
25,
371
],
[
371,
1,
772
]
],
[
[
702,
6,
7950
],
[
7950,
45,
772
]
],
[
[
702,
18,
2966
],
[
2966,
4... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Propafenone"
],
[
"Propafeno... | Anagrelide may lead to a major life threatening interaction when taken with Propafenone and Propafenone (Compound) resembles Carvedilol (Compound)
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Carvedilol (Compound)
Anagrelide (Compound) downregulates HIF1A (Gene) and HIF1A (Gene) is bound by C... |
DB01229 | DB06212 | 973 | 165 | [
"DDInter1377",
"DDInter1833"
] | Paclitaxel | Tolvaptan | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
973,
24,
165
]
],
[
[
973,
63,
1080
],
[
1080,
1,
165
]
],
[
[
973,
6,
8374
],
[
8374,
45,
165
]
],
[
[
973,
21,
28981
],
[
28981,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Tolvaptan (Compound)
Paclitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tolvaptan (Compound)
Paclitaxel (Compound) causes Renal impairment (Side Effect) and Rena... |
DB00446 | DB09498 | 597 | 810 | [
"DDInter351",
"DDInter1715"
] | Chloramphenicol | Strontium chloride Sr-89 | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
597,
24,
810
]
],
[
[
597,
63,
552
],
[
552,
24,
810
]
],
[
[
597,
24,
1555
],
[
1555,
24,
810
]
],
[
[
597,
24,
689
],
[
689,
6... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Car... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00515 | DB10276 | 589 | 1,624 | [
"DDInter387",
"DDInter1623"
] | Cisplatin | Rotavirus vaccine | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
589,
25,
1624
]
],
[
[
589,
24,
1042
],
[
1042,
24,
1624
]
],
[
[
589,
63,
552
],
[
552,
25,
1624
]
],
[
[
589,
24,
1307
],
[
1307,
... | [
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"T... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Carmusti... |
DB00059 | DB09123 | 1,560 | 1,525 | [
"DDInter1404",
"DDInter546"
] | Pegaspargase | Dienogest | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in... | Moderate | 1 | [
[
[
1560,
24,
1525
]
],
[
[
1560,
24,
980
],
[
980,
24,
1525
]
],
[
[
1560,
25,
581
],
[
581,
24,
1525
]
],
[
[
1560,
24,
484
],
[
484,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dienogest"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Dienogest
Pegaspargase may lead to a major life threatening interaction when taken with Infliximab and Infliximab may c... |
DB01281 | DB06674 | 881 | 908 | [
"DDInter5",
"DDInter837"
] | Abatacept | Golimumab | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
881,
25,
908
]
],
[
[
881,
23,
1193
],
[
1193,
62,
908
]
],
[
[
881,
62,
1461
],
[
1461,
23,
908
]
],
[
[
881,
24,
200
],
[
200,
... | [
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Abatacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc glucon... | Abatacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Golimumab
Abatacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin ... |
DB00277 | DB04834 | 1,031 | 276 | [
"DDInter1791",
"DDInter1571"
] | Theophylline | Rapacuronium | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm. | Moderate | 1 | [
[
[
1031,
24,
276
]
],
[
[
1031,
24,
1194
],
[
1194,
23,
276
]
],
[
[
1031,
24,
251
],
[
251,
24,
276
]
],
[
[
1031,
1,
746
],
[
746,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rapacuronium"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Rapacuronium
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and... |
DB09049 | DB14568 | 1,135 | 982 | [
"DDInter1261",
"DDInter1000"
] | Naloxegol | Ivosidenib | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
1135,
24,
982
]
],
[
[
1135,
63,
1101
],
[
1101,
23,
982
]
],
[
[
1135,
24,
241
],
[
241,
24,
982
]
],
[
[
1135,
62,
1478
],
[
1478,
... | [
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitin... |
DB00252 | DB00443 | 362 | 251 | [
"DDInter1460",
"DDInter195"
] | Phenytoin | Betamethasone | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Moderate | 1 | [
[
[
362,
24,
251
]
],
[
[
362,
24,
870
],
[
870,
1,
251
]
],
[
[
362,
24,
1486
],
[
1486,
40,
251
]
],
[
[
362,
6,
8374
],
[
8374,
4... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betamethasone (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone (Compound) resem... |
DB00635 | DB09268 | 1,573 | 1,662 | [
"DDInter1515",
"DDInter1464"
] | Prednisone | Picosulfuric acid | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1573,
24,
1662
]
],
[
[
1573,
24,
1482
],
[
1482,
23,
1662
]
],
[
[
1573,
63,
1252
],
[
1252,
23,
1662
]
],
[
[
1573,
24,
1619
],
[
16... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxi... |
DB00307 | DB08932 | 1,101 | 1,398 | [
"DDInter202",
"DDInter1111"
] | Bexarotene | Macitentan | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Moderate | 1 | [
[
[
1101,
24,
1398
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
1398
]
],
[
[
1101,
21,
29462
],
[
29462,
60,
1398
]
],
[
[
1101,
24,
283
],
[
28... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Macitentan (Compound)
Bexarotene (Compound) causes Influenza (Side Effect) and Influenza (Side Effect) is caused by Macitentan (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedr... |
DB01319 | DB09043 | 34 | 135 | [
"DDInter777",
"DDInter36"
] | Fosamprenavir | Albiglutide | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
34,
24,
135
]
],
[
[
34,
63,
126
],
[
126,
23,
135
]
],
[
[
34,
64,
467
],
[
467,
23,
135
]
],
[
[
34,
63,
870
],
[
870,
24,
... | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
... | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Fosamprenavir may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cau... |
DB01041 | DB01136 | 770 | 772 | [
"DDInter1789",
"DDInter305"
] | Thalidomide | Carvedilol | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
770,
24,
772
]
],
[
[
770,
24,
371
],
[
371,
1,
772
]
],
[
[
770,
6,
9842
],
[
9842,
45,
772
]
],
[
[
770,
21,
28734
],
[
28734,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
],
[... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone (Compound) resembles Carvedilol (Compound)
Thalidomide (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Carvedilol (Compound)
Thalidomide (Compound) causes Immune system disorder (Side Eff... |
DB00736 | DB09143 | 660 | 313 | [
"DDInter676",
"DDInter1701"
] | Esomeprazole | Sonidegib | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Minor | 0 | [
[
[
660,
23,
313
]
],
[
[
660,
40,
837
],
[
837,
23,
313
]
],
[
[
660,
1,
379
],
[
379,
23,
313
]
],
[
[
660,
24,
478
],
[
478,
24,
... | [
[
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sonidegib"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a mi... | Esomeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Esomeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Sonide... |
DB01069 | DB06292 | 401 | 549 | [
"DDInter1533",
"DDInter474"
] | Promethazine | Dapagliflozin | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
401,
24,
549
]
],
[
[
401,
24,
1344
],
[
1344,
40,
549
]
],
[
[
401,
6,
12523
],
[
12523,
45,
549
]
],
[
[
401,
21,
28898
],
[
28898,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Promethazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dapagliflozin (Compound)
Promethazine (Compound) causes Constipation (Side ... |
DB06212 | DB08875 | 165 | 1,618 | [
"DDInter1833",
"DDInter262"
] | Tolvaptan | Cabozantinib | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
165,
24,
1618
]
],
[
[
165,
23,
1135
],
[
1135,
62,
1618
]
],
[
[
165,
63,
723
],
[
723,
24,
1618
]
],
[
[
165,
25,
384
],
[
384,
... | [
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Tolvaptan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Tolvaptan may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant m... |
DB00738 | DB01128 | 485 | 918 | [
"DDInter1420",
"DDInter204"
] | Pentamidine | Bicalutamide | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
485,
24,
918
]
],
[
[
485,
24,
129
],
[
129,
40,
918
]
],
[
[
485,
6,
8374
],
[
8374,
45,
918
]
],
[
[
485,
7,
17537
],
[
17537,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Pentamidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Pentamidine (Compound) upregulates USP6NL (Gene) and USP... |
DB00281 | DB01149 | 608 | 851 | [
"DDInter1066",
"DDInter1274"
] | Lidocaine | Nefazodone | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
608,
24,
851
]
],
[
[
608,
6,
8374
],
[
8374,
45,
851
]
],
[
[
608,
21,
28702
],
[
28702,
60,
851
]
],
[
[
608,
23,
1101
],
[
1101,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Lidocaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound)
Lidocaine (Compound) causes Muscle twitching (Side Effect) and Muscle twitching (Side Effect) is caused by Nefazodone (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bexarotene... |
DB00488 | DB01059 | 196 | 956 | [
"DDInter57",
"DDInter1313"
] | Altretamine | Norfloxacin | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Minor | 0 | [
[
[
196,
23,
956
]
],
[
[
196,
23,
872
],
[
872,
40,
956
]
],
[
[
196,
62,
1176
],
[
1176,
1,
956
]
],
[
[
196,
23,
1539
],
[
1539,
... | [
[
[
"Altretamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Altretamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
... | Altretamine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Altretamine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Co... |
DB01261 | DB08886 | 170 | 637 | [
"DDInter1679",
"DDInter126"
] | Sitagliptin | Asparaginase Erwinia chrysanthemi | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
170,
24,
637
]
],
[
[
170,
63,
167
],
[
167,
24,
637
]
],
[
[
170,
24,
850
],
[
850,
24,
637
]
],
[
[
170,
23,
52
],
[
52,
63,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hy... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Sitagliptin may cause a moderate interaction that could exacerbate diseases when... |
DB06176 | DB08903 | 1,342 | 996 | [
"DDInter1616",
"DDInter170"
] | Romidepsin | Bedaquiline | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Major | 2 | [
[
[
1342,
25,
996
]
],
[
[
1342,
62,
112
],
[
112,
23,
996
]
],
[
[
1342,
24,
713
],
[
713,
63,
996
]
],
[
[
1342,
63,
355
],
[
355,
... | [
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Romidepsin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Romidepsin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate ... |
DB08901 | DB08938 | 1,468 | 1,384 | [
"DDInter1492",
"DDInter1112"
] | Ponatinib | Magaldrate | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
1468,
23,
1384
]
],
[
[
1468,
63,
1220
],
[
1220,
23,
1384
]
],
[
[
1468,
62,
752
],
[
752,
23,
1384
]
],
[
[
1468,
64,
831
],
[
831,
... | [
[
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimeti... |
DB08873 | DB12130 | 74 | 1,017 | [
"DDInter221",
"DDInter1094"
] | Boceprevir | Lorlatinib | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
74,
25,
1017
]
],
[
[
74,
63,
608
],
[
608,
23,
1017
]
],
[
[
74,
64,
175
],
[
175,
24,
1017
]
],
[
[
74,
25,
976
],
[
976,
24,
... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",... | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Boceprevir may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may caus... |
DB01044 | DB06663 | 246 | 1,154 | [
"DDInter809",
"DDInter1398"
] | Gatifloxacin | Pasireotide | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
246,
25,
1154
]
],
[
[
246,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
246,
62,
112
],
[
112,
23,
1154
]
],
[
[
246,
25,
1385
],
[
1385,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caus... | Gatifloxacin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when t... |
DB06168 | DB14762 | 1,531 | 994 | [
"DDInter281",
"DDInter1602"
] | Canakinumab | Risankizumab | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Moderate | 1 | [
[
[
1531,
24,
994
]
],
[
[
1531,
23,
1114
],
[
1114,
23,
994
]
],
[
[
1531,
62,
1461
],
[
1461,
23,
994
]
],
[
[
1531,
63,
4
],
[
4,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Canakinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
... | Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Canakinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitam... |
DB00651 | DB04854 | 746 | 1,291 | [
"DDInter613",
"DDInter713"
] | Dyphylline | Febuxostat | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult pat... | Moderate | 1 | [
[
[
746,
24,
1291
]
],
[
[
746,
40,
1031
],
[
1031,
24,
1291
]
],
[
[
746,
63,
1585
],
[
1585,
40,
372
],
[
372,
24,
1291
]
],
[
[
746,
... | [
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Febuxostat"
]
],
[
[
"Dyphylline",
"{u} (Compound) resembles {v} (Compound)",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a mod... | Dyphylline (Compound) resembles Theophylline (Compound) and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Febuxostat
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Adenosine and Adenosine (Compound) resembles Clofarabine (Compoun... |
DB00762 | DB09098 | 613 | 98 | [
"DDInter973",
"DDInter1700"
] | Irinotecan | Somatrem | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
613,
24,
98
]
],
[
[
613,
24,
1612
],
[
1612,
62,
98
]
],
[
[
613,
24,
336
],
[
336,
24,
98
]
],
[
[
613,
24,
159
],
[
159,
63,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipi... |
DB00176 | DB01225 | 529 | 500 | [
"DDInter770",
"DDInter645"
] | Fluvoxamine | Enoxaparin | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Moderate | 1 | [
[
[
529,
24,
500
]
],
[
[
529,
21,
29173
],
[
29173,
60,
500
]
],
[
[
529,
25,
1039
],
[
1039,
24,
500
]
],
[
[
529,
24,
1317
],
[
1317,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema peripheral"
],
[
"Oedema peripheral",
"{u} (Si... | Fluvoxamine (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Enoxaparin (Compound)
Fluvoxamine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken... |
DB01075 | DB01175 | 1,376 | 318 | [
"DDInter569",
"DDInter672"
] | Diphenhydramine | Escitalopram | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
1376,
24,
318
]
],
[
[
1376,
63,
1230
],
[
1230,
1,
318
]
],
[
[
1376,
6,
10215
],
[
10215,
45,
318
]
],
[
[
1376,
21,
29243
],
[
2924... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Diphenhydramine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Escitalopram (Compound)
Diphenhydramine (Compound) causes Wheezing (Side E... |
DB00701 | DB09045 | 1,091 | 52 | [
"DDInter90",
"DDInter607"
] | Amprenavir | Dulaglutide | Amprenavir is a protease inhibitor used to treat HIV infection. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
1091,
24,
52
]
],
[
[
1091,
24,
170
],
[
170,
23,
52
]
],
[
[
1091,
23,
609
],
[
609,
24,
52
]
],
[
[
1091,
63,
870
],
[
870,
24... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Cla... |
DB00023 | DB00262 | 305 | 552 | [
"DDInter127",
"DDInter302"
] | Asparaginase Escherichia coli | Carmustine | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Moderate | 1 | [
[
[
305,
24,
552
]
],
[
[
305,
24,
1299
],
[
1299,
62,
552
]
],
[
[
305,
24,
1176
],
[
1176,
23,
552
]
],
[
[
305,
24,
1362
],
[
1362,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Carmustine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate dise... |
DB00420 | DB00470 | 508 | 530 | [
"DDInter1532",
"DDInter601"
] | Promazine | Dronabinol | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Moderate | 1 | [
[
[
508,
24,
530
]
],
[
[
508,
24,
1614
],
[
1614,
40,
530
]
],
[
[
508,
6,
6017
],
[
6017,
45,
530
]
],
[
[
508,
63,
701
],
[
701,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Promazine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dronabinol (Compound)
Promazine may cause a moderate interaction that could exacerbate disease... |
DB09330 | DB11113 | 985 | 657 | [
"DDInter1352",
"DDInter307"
] | Osimertinib | Castor oil | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
985,
24,
657
]
],
[
[
985,
64,
1079
],
[
1079,
24,
657
]
],
[
[
985,
25,
927
],
[
927,
63,
657
]
],
[
[
985,
63,
1181
],
[
1181,
... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
],
[
"Telavanc... | Osimertinib may lead to a major life threatening interaction when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Osimertinib may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate ... |
DB00603 | DB04868 | 303 | 478 | [
"DDInter1137",
"DDInter1293"
] | Medroxyprogesterone acetate | Nilotinib | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
303,
24,
478
]
],
[
[
303,
6,
6017
],
[
6017,
45,
478
]
],
[
[
303,
7,
2592
],
[
2592,
46,
478
]
],
[
[
303,
6,
1899
],
[
1899,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (G... | Medroxyprogesterone acetate (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Medroxyprogesterone acetate (Compound) upregulates CEBPD (Gene) and CEBPD (Gene) is upregulated by Nilotinib (Compound)
Medroxyprogesterone acetate (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated ... |
DB00382 | DB00445 | 62 | 322 | [
"DDInter1734",
"DDInter655"
] | Tacrine | Epirubicin | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
62,
24,
322
]
],
[
[
62,
24,
112
],
[
112,
62,
322
]
],
[
[
62,
24,
484
],
[
484,
63,
322
]
],
[
[
62,
63,
482
],
[
482,
24,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Epirubicin
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrect... |
DB00092 | DB13007 | 58 | 1,060 | [
"DDInter40",
"DDInter642"
] | Alefacept | Enfortumab vedotin | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
58,
24,
1060
]
],
[
[
58,
24,
270
],
[
270,
24,
1060
]
],
[
[
58,
63,
599
],
[
599,
24,
1060
]
],
[
[
58,
25,
1011
],
[
1011,
25... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab a... |
DB05015 | DB06643 | 1,077 | 1,136 | [
"DDInter174",
"DDInter500"
] | Belinostat | Denosumab | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1077,
24,
1136
]
],
[
[
1077,
63,
482
],
[
482,
24,
1136
]
],
[
[
1077,
64,
1377
],
[
1377,
24,
1136
]
],
[
[
1077,
25,
1510
],
[
1510... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Belinostat may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause... |
DB00757 | DB01118 | 1,166 | 33 | [
"DDInter581",
"DDInter76"
] | Dolasetron | Amiodarone | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Major | 2 | [
[
[
1166,
25,
33
]
],
[
[
1166,
25,
540
],
[
540,
1,
33
]
],
[
[
1166,
6,
8374
],
[
8374,
45,
33
]
],
[
[
1166,
7,
6952
],
[
6952,
4... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u}... | Dolasetron may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Dolasetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Amiodarone (Compound)
Dolasetron (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulate... |
DB00022 | DB00697 | 268 | 876 | [
"DDInter1408",
"DDInter1821"
] | Peginterferon alfa-2b | Tizanidine | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Major | 2 | [
[
[
268,
25,
876
]
],
[
[
268,
24,
112
],
[
112,
62,
876
]
],
[
[
268,
24,
770
],
[
770,
63,
876
]
],
[
[
268,
24,
912
],
[
912,
24,... | [
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tizanidine
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00539 | DB00694 | 11 | 51 | [
"DDInter1837",
"DDInter485"
] | Toremifene | Daunorubicin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Major | 2 | [
[
[
11,
25,
51
]
],
[
[
11,
6,
7950
],
[
7950,
45,
51
]
],
[
[
11,
7,
10439
],
[
10439,
46,
51
]
],
[
[
11,
18,
1918
],
[
1918,
57,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daunorubicin"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Dauno... | Toremifene (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound)
Toremifene (Compound) upregulates PROS1 (Gene) and PROS1 (Gene) is upregulated by Daunorubicin (Compound)
Toremifene (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Daunorubicin (Compound)
Toremifene... |
DB00902 | DB01168 | 104 | 1,053 | [
"DDInter1168",
"DDInter1526"
] | Methdilazine | Procarbazine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
104,
24,
1053
]
],
[
[
104,
40,
9
],
[
9,
63,
1053
]
],
[
[
104,
63,
100
],
[
100,
24,
1053
]
],
[
[
104,
1,
830
],
[
830,
63,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u}... | Methdilazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a m... |
DB06605 | DB12141 | 1,409 | 971 | [
"DDInter108",
"DDInter817"
] | Apixaban | Gilteritinib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1409,
24,
971
]
],
[
[
1409,
24,
1097
],
[
1097,
24,
971
]
],
[
[
1409,
63,
1335
],
[
1335,
24,
971
]
],
[
[
1409,
24,
283
],
[
283,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcar... |
DB01039 | DB09564 | 535 | 1,296 | [
"DDInter718",
"DDInter930"
] | Fenofibrate | Insulin degludec | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
535,
24,
1296
]
],
[
[
535,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
535,
63,
305
],
[
305,
24,
1296
]
],
[
[
535,
40,
429
],
[
429,
... | [
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],... | Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginas... |
DB00619 | DB01118 | 1,419 | 33 | [
"DDInter909",
"DDInter76"
] | Imatinib | Amiodarone | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
1419,
24,
33
]
],
[
[
1419,
24,
540
],
[
540,
1,
33
]
],
[
[
1419,
6,
7950
],
[
7950,
45,
33
]
],
[
[
1419,
18,
6448
],
[
6448,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Imatinib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Amiodarone (Compound)
Imatinib (Compound) downregulates CTSD (Gene) and CTSD (Gene) is upr... |
DB00461 | DB06209 | 598 | 256 | [
"DDInter1254",
"DDInter1508"
] | Nabumetone | Prasugrel | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
598,
25,
256
]
],
[
[
598,
21,
28681
],
[
28681,
60,
256
]
],
[
[
598,
23,
752
],
[
752,
23,
256
]
],
[
[
598,
63,
305
],
[
305,
... | [
[
[
"Nabumetone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Nabumetone",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused... | Nabumetone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Nabumetone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken wit... |
DB00515 | DB12240 | 589 | 110 | [
"DDInter387",
"DDInter1485"
] | Cisplatin | Polatuzumab vedotin | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
589,
24,
110
]
],
[
[
589,
24,
467
],
[
467,
24,
110
]
],
[
[
589,
63,
268
],
[
268,
24,
110
]
],
[
[
589,
25,
770
],
[
770,
24,... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterfero... |
DB00468 | DB14568 | 1,424 | 982 | [
"DDInter1557",
"DDInter1000"
] | Quinine | Ivosidenib | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
1424,
25,
982
]
],
[
[
1424,
23,
112
],
[
112,
23,
982
]
],
[
[
1424,
63,
1101
],
[
1101,
23,
982
]
],
[
[
1424,
25,
543
],
[
543,
... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",... | Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.